PERSONAL INFORMATION

Marco Salvetti

Affiliation - Sapienza University of Rome
Department – Neuroscienze, Salute Mentale e Organi di Senso (NESMOS)
Address

marco.salvetti@uniroma1.it

Gender M | *Date of birth* *Nationality* Italian

University
☐X Full professor

EMPLOYMENTS

2016 - present
Full Professor of Neurology
Sapienza University

2018 – present
Director of Neurology
Sapienza University – S. Andrea University Hospital

2022 – present
Director, Department of Neuroscience, Mental Health and Sensory Organs
Sapienza University

2011-2018
Member of the Institutional Review Board of Policlinico Umberto I and S. Andrea University Hospital

2022 - present
Chair, Neurology residency training programme
Sapienza University

2020 - 2020
Director of the Doctorate School in Neuroscience
Sapienza University

2017 - 2020
Coordinator, PhD in Clinical and Experimental Neuroscience and Psychiatry
Sapienza University

2010 - 2011
Member of the University Scientific Board
Sapienza University

2007 - 2022
Co-coordinator, "Percorso di Eccellenza" (MD/PhD progam-like initiative)
Sapienza University –Faculty of medicine and Psychology

2002-2013
Head of the Department Unit – Center for Experimental Neurological Therapies – S. Andrea University Hospital

2005 - 2007
Director, Master in Research Methodologies for the Development of new Therapies
Sapienza University

EDUCATION AND ACADEMIC DEGREES

Replace with EQF (or other) level if relevant

1986 M.D.
Sapienza University of Rome

1987-1990 Specialization in Neurology
Sapienza University of Rome

1989-1990 Training in Neuroimmunology
Max Planck Society for Multiple Sclerosis - Germany

ACHIEVEMENTS AND AWARD

Awards

2021-present Academic Chair, Industry Forum of the International Progressive Multiple Sclerosis Alliance

2010-present Member of the Scientific Steering Committee of the International Progressive Multiple Sclerosis Alliance

2018-present Member of the Board of Directors of the Italian Multiple Sclerosis Society

2020-present Member of the Board of Directors of the Accademia Medica di Roma

2018-2020 Member of the Scientific Panel on Neuroimmunology of the European Academy of Neurology

2018-2020 Member of the External Advisory Board of the H2020 Multi-Act project

2016 - present Member of the Scientific Steering Committee of the Italian Neuroimmunology Society

2015-2020 Coordinator of the Neuroimmunology Study Group of the Italian Neurology Society

2014-2019 Member of the ECTRIMS Council

2009-present Member of the Medical and scientific Board of the Multiple Sclerosis International Federation

2011 Member of the Expert Panel for the evaluation of independent research on drugs, Italian Pharma Agency (AIFA)

1997-2018 Served as a member of the Scientific Secretariat or Scientific Steering Committee of the Italian Multiple Sclerosis Society (various mandates)

1999 Rita Levi-Montalcini Award for research in Multiple Sclerosis

1989-1990 Visiting scientist – Max Planck Society for Multiple Sclerosis

Editorial activity Member of the Editorial Board – Neurological Sciences

Major invited presentations

Accademia Medica di Roma – Invited Lecture on Epstein Barr virus in Multiple Sclerosis (2008)

Pathways to Cures Global Summit, New York 1-3 May 2023 – Invited Lecture on Ending MS, primary prevention

Grants (last 5 years)

"COVID-19 and MS 2021". Italian Multiple Sclerosis Society.
Project: "SARS-CoV-2 and multiple sclerosis – has the interplay started? Study on the impact of SARS-CoV-2 infection and anti-SARS-CoV-2 vaccine on multiple sclerosis.
Three-year project (2022-2024).
559.500,00 Euros. P.I. Marco Salvetti

Sapienza University. Progetti di Ateneo Medi
Project: Looking for final effectors of regulome alterations in MS: LMP1-mediated dysregulation of AID in MS pathogenesis
12.500 Euros. P.I. Marco Salvetti

Sapienza University Grandi Attrezzature di interesse comune
Project: Application of a genetic sequencing core lab (gscl) for the omics sciences in medicine
433.000,00 euros. P.I. Massimo Volpe, CO-PI Marco Salvetti, Andrea Vecchione

PRIN 2017
Drug repurposing as a novel strategy to discover pro-regenerative therapies for neurological diseases: the challenge of progressive multiple sclerosis
94.859 Euros. Coordinator Maria Pia Abbracchio. Research Unit P.I. Marco Salvetti

Sapienza University Grandi Attrezzature di interesse comune
Progetto: Uso della Digital droplet PCR negli studi di patologie mono- e multifattoriali
70,000 Euros. P.I. Marco Salvetti

Patents

Glucose derivatives bound to arsenic for use in the treatment of tumour
WO EP US IT ITRM20120058A1 Marco Salvetti Pisanelli Giovanni Codacci
Priority 2012-02-20 • Filed 2012-02-20 • Published 2013-08-21

Epstein Barr virus genotipic variants and uses thereof as risk predictors, biomarkers and therapeutic targets of multiple sclerosis
WO EP US IT ITRM20130206A1 Marco Salvetti Univ Roma
Priority 2013-04-05 • Filed 2013-04-05 • Published 2014-10-06

Biomarkers of multiple sclerosis
WO IT ITRM20060640A1 Marco Salvetti Univ Roma
Priority 2006-12-01 • Filed 2006-12-01 • Published 2008-06-02

A process for the production of immunoglobulines extracted from human plasma for therapeutic use, for the neutralization of the epstein-barr virus, and the medicine containing said immunoglobulins
WO IT ITRM20090558A1 Marco Salvetti Michele Pitaro
Priority 2009-11-03 • Filed 2009-11-03 • Published 2011-05-04

Diagnostic methods for the detection of Epstein Barr virus (EBV) in EBV-related pethologies by MRI and PET and cytofluorimetry
IT ITRM20090559A1 Marco Salvetti Michele Pitaro
Priority 2009-11-03 • Filed 2009-11-03 • Published 2011-05-04

ADDITIONAL INFORMATION

Publications

total number of publications in peer-review journals: 280
total Impact Factor (IF) (average IF/paper): 6.8
total number of citations: 11324
H index: 46

Aloisi F, Salvetti M. Epstein-Barr virus and multiple sclerosis: supporting causality. Lancet Neurol. 2022 Apr;21(4):300-301. doi: 10.1016/S1474-4422(22)00086-2. PMID: 35305331.

Procaccini C, Garavelli S, Carbone F, Di Silvestre D, La Rocca C, Greco D, Colamatteo A, Lepore MT, Russo C, De Rosa G, Faicchia D, Prattichizzo F, Grossi S, Campomenosi P, Buttari F, Mauri P, Uccelli A, Salvetti M, Brescia Morra V, Vella D, Galgani M, Mottola M, Zuccarelli B, Lanzillo R, Maniscalco GT, Centonze D, de Candia P, Matarese G. Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential. Immunity. 2021 Jul 13;54(7):1543-1560.e6. doi: 10.1016/j.immuni.2021.04.014. Epub 2021 May 17. PMID: 34004141.

Dangond F, Donnelly A, Hohlfeld R, Lubetzki C, Kohlhaas S, Leocani L, Ciccarelli O, Stankoff B, Sormani MP, Chataway J, Bozzoli F, Cucca F, Melton L, Coetzee T, Salvetti M. Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal. Nat Rev Neurol. 2021 Mar;17(3):185-192. doi: 10.1038/s41582-020-00446-9. Epub 2021 Jan 22. PMID: 33483719.

Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratin P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; Musc-19 Study Group. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9. PMID: 33480077; PMCID: PMC8013440.

International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019 Sep 27;365(6460):eaav7188. doi: 10.1126/science.aav7188. PMID: 31604244; PMCID: PMC7241648.

Salvetti M, Lubetzki C, Kapoor R, Ristori G, Costa E, Battaglia MA, Andreaus M, Abbracchio MP, Matarese G, Zaratin P. Steps towards Collective Sustainability in Biomedical Research. Trends Mol Med. 2018 May;24(5):429-432. doi: 10.1016/j.molmed.2018.03.001. Epub 2018 Mar 24. PMID: 29588144.

De Rosa V, Galgani M, Porcellini A, Colamatteo A, Santopaolo M, Zuchegna C, Romano A, De Simone S, Procaccini C, La Rocca C, Carrieri PB, Maniscalco GT, Salvetti M, Buscarinu MC, Franzese A, Mozzillo E, La Cava A, Matarese G. Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat Immunol. 2015 Nov;16(11):1174-84. doi: 10.1038/ni.3269. Epub 2015 Sep 28. PMID: 26414764; PMCID: PMC4868085.

Mechelli R, Manzari C, Policano C, Annese A, Picardi E, Umeton R, Fornasiero A, D'Erchia AM, Buscarinu MC, Agliardi C, Annibali V, Serafini B, Rosicarelli B, Romano S, Angelini DF, Ricigliano VA, Buttari F, Battistini L, Centonze D, Guerini FR, D'Alfonso S, Pesole G, Salvetti M, Ristori G. Epstein-Barr virus genetic variants are associated with multiple sclerosis. Neurology. 2015 Mar 31;84(13):1362-8. doi: 10.1212/WNL.0000000000001420. Epub 2015 Mar 4. PMID: 25740864; PMCID: PMC4388746.

Mechelli R, Umeton R, Policano C, Annibali V, Coarelli G, Ricigliano VA, Vittori D, Fornasiero A, Buscarinu MC; International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium,2, Romano S, Salvetti M, Ristori G. A "candidate-interactome" aggregate analysis of genome-wide association data in multiple sclerosis. PLoS One. 2013 May 16;8(5):e63300. doi: 10.1371/journal.pone.0063300. PMID: 23696811; PMCID: PMC3655974.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, et al.. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251. PMID: 21833088; PMCID: PMC3182531.

Rome, January13, 2024
Fornisco consenso al *trattamento dei dati personali indicati nel curriculum ai sensi del D.lgs. 196/2003, come modificato dal Regolamento UE 679/2016, recepito dal Decreto n. 101 del 10/08/2018;*
L*e dichiarazioni in esso contenute sono rese ai sensi del D.P.R. 445/2000*

Prof. Marco Salvetti